Noxopharm Limited (NOXOF)
NOXOF Stock Price Chart
Explore Noxopharm Limited interactive price chart. Choose custom timeframes to analyze NOXOF price movements and trends.
NOXOF Company Profile
Discover essential business fundamentals and corporate details for Noxopharm Limited (NOXOF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jan 2020
Employees
—
Website
https://www.noxopharm.comCEO
Gisela Mautner
Description
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
NOXOF Financial Timeline
Browse a chronological timeline of Noxopharm Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 20 Jul 2025
Earnings released on 30 Apr 2025
Earnings released on 25 Feb 2025
Earnings released on 28 Oct 2024
Earnings released on 22 Jul 2024
EPS came in at -$0.00 , while revenue for the quarter reached $396.16K .
Earnings released on 28 Apr 2024
EPS came in at -$0.00 , while revenue for the quarter reached $385.56K .
Earnings released on 26 Feb 2024
EPS came in at -$0.01 , while revenue for the quarter reached $412.56K .
Earnings released on 21 Jan 2024
EPS came in at -$0.00 , while revenue for the quarter reached $387.79K .
Earnings released on 30 Jun 2023
EPS came in at -$0.02 , while revenue for the quarter reached $884.71K .
Earnings released on 31 Mar 2023
EPS came in at -$0.01 , while revenue for the quarter reached $894.56K .
Earnings released on 31 Dec 2022
EPS came in at -$0.01 , while revenue for the quarter reached $1.14M .
Earnings released on 30 Sept 2022
EPS came in at -$0.01 , while revenue for the quarter reached $1.08M .
Earnings released on 30 Jun 2022
EPS came in at -$0.02 , while revenue for the quarter reached $1.25M .
Earnings released on 31 Mar 2022
EPS came in at -$0.01 , while revenue for the quarter reached $1.37M .
Earnings released on 30 Dec 2021
EPS came in at -$0.02 , while revenue for the quarter reached $648.30K .
Earnings released on 30 Sept 2021
EPS came in at -$0.01 , while revenue for the quarter reached $647.24K .
Earnings released on 30 Jun 2021
EPS came in at -$0.01 , while revenue for the quarter reached $1.60M .
Earnings released on 31 Mar 2021
EPS came in at -$0.00 , while revenue for the quarter reached $1.62M .
Earnings released on 30 Dec 2020
EPS came in at -$0.02 , while revenue for the quarter reached $519.57K .
Earnings released on 30 Sept 2020
EPS came in at -$0.01 , while revenue for the quarter reached $485.45K .
NOXOF Stock Performance
Access detailed NOXOF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.